0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Astria Therapeutics Inc

Healthcare US ATXS

9.17USD
0.17(1.89%)

Last update at 2024-04-25T20:00:00Z

Day Range

8.779.19
LowHigh

52 Week Range

4.2616.28
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -51.83400M -194.91200M -37.30000M -26.29300M -25.87000M
Minority interest - - - - -
Net income -50.16500M -30.17300M -37.06400M -26.24300M -25.87000M
Selling general administrative 19.24M 14.81M 11.85M 8.77M 9.33M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - 0.03M 0.12M
Ebit -53.50300M -194.97600M -37.03500M -27.08800M -25.77000M
Ebitda -53.50300M 134.26M -37.43500M -26.26700M -25.65100M
Depreciation and amortization 1.67M 329.23M - 0.82M 0.12M
Non operating income net other 1.67M - - - -
Operating income -53.50300M -194.97600M -37.43500M -27.08800M -26.37100M
Other operating expenses 53.50M 30.36M 37.44M 27.09M 26.37M
Interest expense 1.67M 0.06M 0.24M 0.00000M 0.10M
Tax provision - - - - -
Interest income 1.72M 0.12M 0.24M 0.84M 0.42M
Net interest income 1.72M 0.12M 0.24M 0.84M 0.33M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.66900M -164.73900M -0.23600M -0.05000M 0.60M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 53.50M 30.36M 37.44M 27.09M 26.37M
Cost of revenue - - - - -
Total other income expense net 1.67M 0.06M 0.14M 0.80M 0.18M
Discontinued operations - - - - -
Net income from continuing ops -51.83400M -194.91200M -37.30000M -26.29300M -25.87000M
Net income applicable to common shares -51.83400M -219.34900M -37.30000M -26.29300M -25.87000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 230.63M 127.51M 47.46M 41.78M 39.17M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.25M 1.57M 1.40M 2.71M 1.34M
Total liab 9.42M 5.20M 6.79M 6.06M 4.23M
Total stockholder equity 221.22M 122.31M 40.67M 35.72M 34.94M
Deferred long term liab - - - - -
Other current liab -0.78800M 3.28M 4.20M 2.61M 2.76M
Common stock 0.03M 0.01M 0.02M 0.01M 0.00700M
Capital stock 96.43M 96.41M 0.02M 0.01M 0.00700M
Retained earnings -507.64300M -455.80900M -260.89700M -223.59700M -197.30400M
Other liab - - - - 0.06M
Good will - - - - -
Other assets 3.25M 0.04M 0.17M 0.47M 0.25M
Cash 20.52M 86.51M 24.93M 9.90M 15.29M
Cash and equivalents - - - - -
Total current liabilities 0.58M 5.20M 6.39M 5.03M 4.17M
Current deferred revenue - - - - -
Net debt -19.58600M -86.14300M -23.88400M -7.64600M -15.29400M
Short term debt 0.58M 0.36M 0.65M 1.23M -
Short long term debt - - - - -
Short long term debt total 0.94M 0.36M 1.05M 2.25M -
Other stockholder equity 632.51M 481.71M 301.55M 259.31M 232.24M
Property plant equipment 0.95M 0.39M 0.97M 2.35M -
Total current assets 226.44M 127.08M 46.33M 38.96M 38.91M
Long term investments - - - - -
Net tangible assets 124.82M 25.91M 40.67M 35.72M 34.94M
Short term investments 205.91M 39.00M 20.00M 26.34M 22.28M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.79M 1.56M 1.54M 1.20M 1.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.07900M - - - -0.00400M
Additional paid in capital - - - - -
Common stock total equity 0.03M - 0.02M 0.01M 0.00700M
Preferred stock total equity 96.40M - - - -
Retained earnings total equity -507.64300M - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.25M 0.04M 0.17M 0.47M 0.20M
Deferred long term asset charges - - - - -
Non current assets total 4.20M 0.44M 1.13M 2.82M 0.25M
Capital lease obligations 0.94M 0.36M 1.05M 2.25M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -167.03800M -19.00000M 6.33M -4.07000M -22.27400M
Change to liabilities 3.64M -1.96500M 0.35M -0.21100M 0.66M
Total cashflows from investing activities -167.12900M -12.55500M 6.30M -4.08200M -21.90500M
Net borrowings - - - - -2.84800M
Total cash from financing activities 144.72M 104.28M 40.86M 25.62M 44.30M
Change to operating activities - -1.34000M 3.02M -1.65900M 0.10M
Net income -51.83400M -194.91200M -37.30000M -26.29300M -25.87000M
Change in cash -65.94100M 61.58M 14.68M -5.03100M -1.07500M
Begin period cash flow 86.63M 25.05M 10.38M 15.41M 16.48M
End period cash flow 20.69M 86.63M 25.05M 10.38M 15.41M
Total cash from operating activities -43.53300M -30.15100M -32.48500M -26.56900M -23.46500M
Issuance of capital stock 144.64M 104.26M 40.83M 25.57M 47.14M
Depreciation - - - 0.03M 0.12M
Other cashflows from investing activities - - - - -
Dividends paid - 24.44M - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 107.73M - - - -
Other cashflows from financing activities 0.08M 24.46M 0.03M 0.05M 0.00400M
Change to netincome 4.67M 168.07M 1.45M 1.59M 1.52M
Capital expenditures 0.09M 0.02M 0.03M 0.01M 0.02M
Change receivables - - - - -
Cash flows other operating -0.00600M - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -65.94100M - - - -
Change in working capital 2.65M -3.30500M 3.37M -1.87000M 0.76M
Stock based compensation 4.55M 3.36M - 1.51M 1.77M
Other non cash items 1.10M 164.70M 1.45M 0.03M 0.06M
Free cash flow -43.62400M -30.17200M -32.51800M -26.58100M -23.44700M

Fundamentals

  • Previous Close 9.00
  • Market Cap272.22M
  • Volume1322207
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-32.38000M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.12

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ATXS
Astria Therapeutics Inc		 0.17 1.89% 9.17 - - - 2.46 -2.0056
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Astria Therapeutics Inc

100 High Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Ms. Jill C. Milne Ph.D. Co-Founder, CEO, Pres & Director 1968
Mr. Noah Clauser CPA Chief Financial Officer 1974
Dr. Andrew J. Nichols Ph.D. Chief Scientific Officer 1961
Mr. Benjamin S. Harshbarger J.D. Chief Legal Officer 1969
Ms. Keri McGrail Sr. VP of HR NA
Ms. Andrea L. Matthews Sr. VP of Corp. Affairs NA
Mr. Andrew A. Komjathy Chief Commercial Officer 1964
Dr. Anthony Christopher Stevens M.D. Interim Chief Medical Officer 1959
Dr. Christopher J. Morabito M.D. Chief Medical Officer 1970

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).